Review

Monogenic disorders of obesity and body fat distribution

Correspondence to: Abhimanyu Garg

Recently, great progress has been made towards understanding the molecular basis of body fat regulation. Identification of mutations in several genes in spontaneous monogenic animal models of obesity and development of transgenic models have indicated the physiological roles of many genes in the regulation of body fat distribution. In humans, mutations in leptin, leptin receptor, prohormone convertase 1 (PC1), pro-opiomelanocortin (POMC), melanocortin 4-receptor (MC4-R), and peroxisome proliferator-activated receptor (PPAR) 2 genes have been described in patients with severe obesity. Most of these obesity disorders exhibit a distinct phenotype with varying degrees of hypothalamic and pituitary dysfunction and a recessive inheritance, whereas MC4-R mutation has a nonsyndromic phenotype with dominant inheritance. These mutations suggest the critical role of central signaling systems composed of leptin/leptin receptor and -melanocyte stimulating hormone/MC4-R in human energy homeostasis. Although the genetic basis of monogenic disorders of body fat distribution, such as congenital generalized lipodystrophy and familial partial lipodystrophy, Dunnigan variety, is still unknown, the genes for these have recently been localized to chromosomes 9q34 and 1q21-22, respectively. The advances in our knowledge of the phenotypic manifestations and underlying molecular mechanisms of genetic body fat disorders may lead to better treatment and prevention of obesity and other disorders of adipose tissue in the future.—Chen, D., and A. Garg. Monogenic disorders of obesity and body fat distribution. J. Lipid Res. 1999. 40: 1735;–1746.

Supplementary key words: obesity, congenital generalized lipodystrophy, familial partial lipodystrophy, leptin, leptin receptor, melanocyte-stimulating hormone, melanocortin receptors

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				F. Minvielle, D. Gourichon, S. Ito, M. Inoue-Murayama, and S. Riviere Effects of the Dominant Lethal Yellow Mutation on Reproduction, Growth, Feed Consumption, Body Temperature, and Body Composition of the Japanese Quail Poult. Sci., August 1, 2007; 86(8): 1646 - 1650. [Abstract] [Full Text] [PDF]

				R. Branson, N. Potoczna, J. G. Kral, K.-U. Lentes, M. R. Hoehe, and F. F. Horber Binge Eating as a Major Phenotype of Melanocortin 4 Receptor Gene Mutations N. Engl. J. Med., March 20, 2003; 348(12): 1096 - 1103. [Abstract] [Full Text] [PDF]

				J. F. List and J. F. Habener Defective Melanocortin 4 Receptors in Hyperphagia and Morbid Obesity N. Engl. J. Med., March 20, 2003; 348(12): 1160 - 1163. [Full Text] [PDF]

				X.-Y. Lu, K.-R. Shieh, M. Kabbaj, G. S. Barsh, H. Akil, and S. J. Watson Diurnal Rhythm of Agouti-Related Protein and Its Relation to Corticosterone and Food Intake Endocrinology, October 1, 2002; 143(10): 3905 - 3915. [Abstract] [Full Text] [PDF]

				S. Franckhauser, S. Munoz, A. Pujol, A. Casellas, E. Riu, P. Otaegui, B. Su, and F. Bosch Increased Fatty Acid Re-esterification by PEPCK Overexpression in Adipose Tissue Leads to Obesity Without Insulin Resistance Diabetes, March 1, 2002; 51(3): 624 - 630. [Abstract] [Full Text] [PDF]

				T. Adage, A. J. W. Scheurink, S. F. de Boer, K. de Vries, J. P. Konsman, F. Kuipers, R. A. H. Adan, D. G. Baskin, M. W. Schwartz, and G. van Dijk Hypothalamic, Metabolic, and Behavioral Responses to Pharmacological Inhibition of CNS Melanocortin Signaling in Rats J. Neurosci., May 15, 2001; 21(10): 3639 - 3645. [Abstract] [Full Text] [PDF]

				H. Nishigori, H. Tomura, N. Tonooka, M. Kanamori, S. Yamada, K. Sho, I. Inoue, N. Kikuchi, K. Onigata, I. Kojima, et al. Mutations in the small heterodimer partner gene are associated with mild obesity in Japanese subjects PNAS, December 28, 2000; (2000) 21544398. [Abstract] [Full Text]

				R. A. Hegele, H. Cao, M. W. Huff, and C. M. Anderson LMNA R482Q Mutation in Partial Lipodystrophy Associated with Reduced Plasma Leptin Concentration J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3089 - 3093. [Abstract] [Full Text]

				E. Arioglu, J. Duncan-Morin, N. Sebring, K. I. Rother, N. Gottlieb, J. Lieberman, D. Herion, D. E. Kleiner, J. Reynolds, A. Premkumar, et al. Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes Ann Intern Med, August 15, 2000; 133(4): 263 - 274. [Abstract] [Full Text] [PDF]

				M. Rozhavskaya-Arena, D. W. Lee, M. C. Leinung, and P. Grasso Design of a Synthetic Leptin Agonist: Effects on Energy Balance, Glucose Homeostasis, and Thermoregulation Endocrinology, July 1, 2000; 141(7): 2501 - 2507. [Abstract] [Full Text] [PDF]

				A. M. Rice, J. N. Fain, and S. A. Rivkees A1 Adenosine Receptor Activation Increases Adipocyte Leptin Secretion Endocrinology, April 1, 2000; 141(4): 1442 - 1445. [Abstract] [Full Text] [PDF]

				H. Nishigori, H. Tomura, N. Tonooka, M. Kanamori, S. Yamada, K. Sho, I. Inoue, N. Kikuchi, K. Onigata, I. Kojima, et al. Mutations in the small heterodimer partner gene are associated with mild obesity in Japanese subjects PNAS, January 16, 2001; 98(2): 575 - 580. [Abstract] [Full Text] [PDF]